DEX fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Dextech Medical AB engages in the provision of research and development of drug candidates for urological oncology. It focuses on the treatment of prostate cancer and non-malignant diseases. Its product portfolio includes OsteoDex, SomaDex, CatDex, and PSMADex. The company was founded by Anders R. Holmberg and Sten Nilsson on April 21, 2004 and is headquartered in Uppsala, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
DEX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company